{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:31:32Z","timestamp":1792798292887,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03844-4","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:39:30Z","timestamp":1763620770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review"],"prefix":"10.1007","volume":"46","author":[{"given":"Ali Hendi","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"9 Suppl","key":"3844_CR1","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/01.TP.0000126926.61434.A5","volume":"77","author":"JJ Fung","year":"2004","unstructured":"Fung JJ (2004) Tacrolimus and transplantation: a decade in review. Transplantation 77(9 Suppl):S41\u2013S43","journal-title":"Transplantation"},{"issue":"9","key":"3844_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Miyata S et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 40(9):1256\u20131265","journal-title":"J Antibiot"},{"issue":"5","key":"3844_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/archderm.135.5.574","volume":"135","author":"T Ruzicka","year":"1999","unstructured":"Ruzicka T, Assmann T, Homey B (1999) Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 135(5):574\u2013580","journal-title":"Arch Dermatol"},{"issue":"5","key":"3844_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ajo.2012.12.009","volume":"155","author":"YJ Lee","year":"2013","unstructured":"Lee YJ, Kim SW, Seo KY (2013) Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. Am J Ophthalmol 155(5):804\u2013813","journal-title":"Am J Ophthalmol"},{"key":"3844_CR5","first-page":"7","volume":"4","author":"SS Shoughy","year":"2017","unstructured":"Shoughy SS (2017) Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (London, England) 4:7","journal-title":"Eye Vis (London, England)"},{"issue":"1","key":"3844_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/pharmaceutics14010118","volume":"14","author":"M Barrieu","year":"2022","unstructured":"Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Sautou V (2022) Physicochemical stability of a novel tacrolimus ophthalmic formulation for the treatment of ophthalmic inflammatory diseases. Pharmaceutics 14(1):118","journal-title":"Pharmaceutics"},{"issue":"4","key":"3844_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/2230-973X.106981","volume":"2","author":"P Patel","year":"2012","unstructured":"Patel P, Patel H, Panchal S et al (2012) Formulation strategies for drug delivery of tacrolimus: an overview. Int J Pharm Investig 2(4):169\u2013175","journal-title":"Int J Pharm Investig"},{"issue":"1\u20132","key":"3844_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijpharm.2003.07.010","volume":"267","author":"K Yamashita","year":"2003","unstructured":"Yamashita K, Nakate T, Okimoto K et al (2003) Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267(1\u20132):79\u201391","journal-title":"Int J Pharm"},{"issue":"6","key":"3844_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","volume":"31","author":"JH Tzu","year":"2012","unstructured":"Tzu JH, Utine CA, Stern ME et al (2012) Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea 31(6):649\u2013654","journal-title":"Cornea"},{"issue":"3","key":"3844_CR10","first-page":"177","volume":"30","author":"P Labcharoenwongs","year":"2012","unstructured":"Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N et al (2012) A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 30(3):177\u201384","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"11","key":"3844_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/ICO.0b013e318295e6b9","volume":"32","author":"GD Kymionis","year":"2013","unstructured":"Kymionis GD, Klados NE, Kontadakis GA et al (2013) Treatment of superior limbic keratoconjunctivitis with topical tacrolimus 0.03% ointment. Cornea 32(11):1499\u20131501","journal-title":"Cornea"},{"issue":"333","key":"3844_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2021.03.035","volume":"10","author":"L Rebibo","year":"2021","unstructured":"Rebibo L, Tam C, Sun Y et al (2021) Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. J Control Release: Off J Control Release Soc 10(333):283\u2013297","journal-title":"J Control Release: Off J Control Release Soc"},{"key":"3844_CR13","doi-asserted-by":"publisher","first-page":"798998","DOI":"10.3389\/fphar.2022.798998","volume":"13","author":"MA Albarry","year":"2022","unstructured":"Albarry MA, Parekh M, Ferrari S et al (2022) Incremental concentrations of tacrolimus eye drops as a strategy for the management of severe vernal keratoconjunctivitis. Front Pharmacol 13:798998","journal-title":"Front Pharmacol"},{"issue":"2","key":"3844_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11587010-000000000-00000","volume":"25","author":"J Zhai","year":"2011","unstructured":"Zhai J, Gu J, Yuan J et al (2011) Tacrolimus in the treatment of ocular diseases. BioDrugs\u202f:Clin Immunother Biopharm Gene Ther 25(2):89\u2013103","journal-title":"BioDrugs :Clin Immunother Biopharm Gene Ther"},{"issue":"7","key":"3844_CR15","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.ophtha.2016.02.044","volume":"123","author":"TB Abud","year":"2016","unstructured":"Abud TB, Amparo F, Saboo US et al (2016) A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease. Ophthalmology 123(7):1449\u20131457","journal-title":"Ophthalmology"},{"issue":"1","key":"3844_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/0974-9233.164616","volume":"23","author":"AM Al-Amri","year":"2016","unstructured":"Al-Amri AM, Mirza AG, Al-Hakami AM (2016) Tacrolimus ointment for treatment of vernal keratoconjunctivitis. Middle East Afr J Ophthalmol 23(1):135\u2013138","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"11","key":"3844_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1097\/ICO.0000000000000918","volume":"35","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Agrawal D (2016) Tacrolimus in corticosteroid-refractory vernal keratoconjunctivitis. Cornea 35(11):1444\u20131448","journal-title":"Cornea"},{"issue":"3","key":"3844_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000478704","volume":"59","author":"Q Wan","year":"2018","unstructured":"Wan Q, Tang J, Han Y et al (2018) Therapeutic effect of 0.1% Tacrolimus eye drops in the tarsal form of vernal keratoconjunctivitis. Ophthalmic Res 59(3):126\u2013134","journal-title":"Ophthalmic Res"},{"issue":"5","key":"3844_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00417-019-04287-1","volume":"257","author":"FY Liu","year":"2019","unstructured":"Liu FY, Liu HY, Chu HS et al (2019) Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 257(5):967\u2013974","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3844_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/ACI.0000000000000560","volume":"19","author":"N Erdinest","year":"2019","unstructured":"Erdinest N, Ben-Eli H, Solomon A (2019) Topical tacrolimus for allergic eye diseases. Curr Opin Allergy Clin Immunol 19(5):535\u2013543","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"3844_CR21","doi-asserted-by":"publisher","first-page":"650083","DOI":"10.3389\/fmed.2021.650083","volume":"8","author":"M Chen","year":"2021","unstructured":"Chen M, Wei A, Ke B et al (2021) Combination of 0.05% azelastine and 0.1% tacrolimus eye drops in children with vernal keratoconjunctivitis: a prospective study. Front Med Lausanne 8:650083","journal-title":"Front Med Lausanne"},{"issue":"2","key":"3844_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.51329\/mehdiophthal1446","volume":"11","author":"M Eltagoury","year":"2022","unstructured":"Eltagoury M, AbouSamra W, Ghoneim E (2022) Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial. Med Hypothesis Discov Innov Ophthalmol J 11(2):52\u201363","journal-title":"Med Hypothesis Discov Innov Ophthalmol J"},{"key":"3844_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2147\/OPTH.S99157","volume":"10","author":"SS Shoughy","year":"2016","unstructured":"Shoughy SS, Jaroudi MO, Tabbara KF (2016) Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis. Clinic Ophthalmol (Auckland, NZ) 10:643\u2013647","journal-title":"Clinic Ophthalmol (Auckland, NZ)"},{"key":"3844_CR24","doi-asserted-by":"publisher","first-page":"112255","DOI":"10.1016\/j.colsurfb.2021.112255","volume":"211","author":"D Modi","year":"2022","unstructured":"Modi D, Nirmal J, Warsi MH et al (2022) Formulation and development of tacrolimus-gellan gum nanoformulation for treatment of dry eye disease. Colloids Surf, B 211:112255","journal-title":"Colloids Surf, B"},{"issue":"2","key":"3844_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.xphs.2021.09.038","volume":"111","author":"Garg V Mohammad","year":"2022","unstructured":"Mohammad Garg V, Nirmal J et al (2022) Topical tacrolimus progylcosomes nano-vesicles as a potential therapy for experimental dry eye syndrome. J Pharmaceutical Sci. 111(2):479\u2013484","journal-title":"J Pharmaceutical Sci."},{"issue":"2","key":"3844_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12016-023-08970-4","volume":"65","author":"G Bruschi","year":"2023","unstructured":"Bruschi G, Ghiglioni DG, Cozzi L et al (2023) Vernal keratoconjunctivitis: a systematic review. Clin Rev Allergy Immunol 65(2):277\u2013329","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"3844_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/iid3.278","volume":"8","author":"G Bruschi","year":"2020","unstructured":"Bruschi G, Ghiglioni DG, Osnaghi S et al (2020) Role of ocular cytology in vernal keratoconjunctivitis. Immun Inflamm Dis 8(1):3\u20137","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"3844_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/bmt.2009.249","volume":"45","author":"PM Tam","year":"2010","unstructured":"Tam PM, Young AL, Cheng LL et al (2010) Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant 45(5):957\u2013958","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3844_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ajo.2014.11.035","volume":"159","author":"JW Jung","year":"2015","unstructured":"Jung JW, Lee YJ, Yoon SC et al (2015) Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol 159(3):519\u201327.e1","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"3844_CR30","first-page":"305","volume":"53","author":"DM Xiang","year":"2017","unstructured":"Xiang DM, Wang YX, Jia YN et al (2017) The observation of tacrolimus eye drops preventing the early immunological rejection after penetrating keratoplasty for fungal keratitis. [Zhonghua yan ke za zhi] Chin J Ophthalmol. 53(4):305\u2013310","journal-title":"[Zhonghua yan ke za zhi] Chin J Ophthalmol."},{"issue":"4","key":"3844_CR31","first-page":"3260","volume":"20","author":"Y Zang","year":"2020","unstructured":"Zang Y, Li S, Ruan F et al (2020) Tacrolimus dye drop treatment for the management of early post-operative intraocular inflammation after therapeutic keratoplasty for severe infectious keratitis. Exp Ther Med 20(4):3260\u20133268","journal-title":"Exp Ther Med"},{"issue":"12","key":"3844_CR32","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41433-021-01855-w","volume":"36","author":"SL Painter","year":"2022","unstructured":"Painter SL, Rana M, Barua A et al (2022) Outcomes following tacrolimus systemic immunosuppression for penetrating keratoplasty in infants and young children. Eye (Lond) 36(12):2286\u20132293","journal-title":"Eye (Lond)"},{"issue":"3","key":"3844_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1399-3046.2006.00666.x","volume":"11","author":"MH Albert","year":"2007","unstructured":"Albert MH, Becker B, Schuster FR et al (2007) Oral graft vs host disease in children\u2013treatment with topical tacrolimus ointment. Pediatr Transplant 11(3):306\u201311","journal-title":"Pediatr Transplant"},{"issue":"4","key":"3844_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pai.12197","volume":"25","author":"P Vichyanond","year":"2014","unstructured":"Vichyanond P, Pacharn P, Pleyer U et al (2014) Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol 25(4):314\u2013322","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"3844_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11882-013-0345-0","volume":"13","author":"P Vichyanond","year":"2013","unstructured":"Vichyanond P, Kosrirukvongs P (2013) Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep 13(3):308\u2013314","journal-title":"Curr Allergy Asthma Rep"},{"issue":"10","key":"3844_CR36","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.4049\/jimmunol.144.10.3891","volume":"144","author":"R Cirillo","year":"1990","unstructured":"Cirillo R, Triggiani M, Siri L, Ciccarelli A, Pettit GR, Condorelli MARIO, Marone G (1990) Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 144(10):3891\u20133897","journal-title":"J Immunol"},{"issue":"3","key":"3844_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.1365-2222.2003.01610.x","volume":"33","author":"KE Plath","year":"2003","unstructured":"Plath KE, Grabbe J, Gibbs BF (2003) Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils. Clin Exp Allergy 33(3):342\u2013350","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"3844_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/eye.2011.75","volume":"25","author":"A Kheirkhah","year":"2011","unstructured":"Kheirkhah A, Zavareh MK, Farzbod F et al (2011) Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond) 25(7):872\u2013880","journal-title":"Eye (Lond)"},{"issue":"4","key":"3844_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3341\/kjo.2012.26.4.241","volume":"26","author":"EH Ryu","year":"2012","unstructured":"Ryu EH, Kim JM, Laddha PM et al (2012) Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol 26(4):241\u2013247","journal-title":"Korean J Ophthalmol"},{"issue":"11","key":"3844_CR40","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/ICO.0000000000000247","volume":"33","author":"RC Ghanem","year":"2014","unstructured":"Ghanem RC, Vargas JF, Ghanem VC (2014) Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. Cornea 33(11):1210\u20131213","journal-title":"Cornea"},{"issue":"5","key":"3844_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00417-014-2611-9","volume":"252","author":"E Levinger","year":"2014","unstructured":"Levinger E, Trivizki O, Shachar Y et al (2014) Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 252(5):811\u2013816","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3844_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0161-6420(91)32280-2","volume":"98","author":"LP Fong","year":"1991","unstructured":"Fong LP, Sainz de la Maza M, Rice BA et al (1991) Immunopathology of scleritis. Ophthalmology 98(4):472\u20139","journal-title":"Ophthalmology"},{"issue":"5","key":"3844_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/09273948.2013.854394","volume":"22","author":"G Homayounfar","year":"2014","unstructured":"Homayounfar G, Borkar DS, Tham VM et al (2014) Clinical characteristics of scleritis and episcleritis: results from the Pacific Ocular Inflammation Study. Ocul Immunol Inflamm 22(5):403\u2013404","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"3844_CR44","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","volume":"115","author":"D Miyazaki","year":"2008","unstructured":"Miyazaki D, Tominaga T, Kakimaru-Hasegawa A et al (2008) Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 115(6):988-992.e5","journal-title":"Ophthalmology"},{"issue":"1","key":"3844_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1442-9071.2005.00955.x","volume":"33","author":"AL Young","year":"2005","unstructured":"Young AL, Wong SM, Leung AT et al (2005) Successful treatment of surgically induced necrotizing scleritis with tacrolimus. Clin Experiment Ophthalmol 33(1):98\u201399","journal-title":"Clin Experiment Ophthalmol"},{"key":"3844_CR46","first-page":"112067212110528","volume":"16","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang J, Xu G et al (2021) A case of nodular episcleritis mimicking a solitary giant episcleral mass. Eur J Ophthalmol 16:11206721211052880","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"3844_CR47","volume":"15","author":"AH Alghamdi Sr","year":"2023","unstructured":"Alghamdi AH Sr (2023) Treatment of steroid-resistant nodular episcleritis with tacrolimus: a case report. Cureus 15(10):e47057","journal-title":"Cureus"},{"issue":"3","key":"3844_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/02713689509033516","volume":"14","author":"N Hikita","year":"1995","unstructured":"Hikita N, Chan CC, Whitcup SM et al (1995) Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Curr Eye Res 14(3):209\u2013214","journal-title":"Curr Eye Res"},{"issue":"1","key":"3844_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1076\/ocii.6.1.51.8079","volume":"6","author":"SM Whitcup","year":"1998","unstructured":"Whitcup SM, Pleyer U, Lai JC et al (1998) Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 6(1):51\u201356","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"3844_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1566524017666170807144009","volume":"17","author":"S De Majumdar","year":"2017","unstructured":"De Majumdar S, Subinya M, Korward J et al (2017) A low concentration of Tacrolimus\/Semifluorinated alkane (SFA) eyedrop suppresses intraocular inflammation in experimental models of uveitis. Curr Mol Med 17(3):211\u2013220","journal-title":"Curr Mol Med"},{"key":"3844_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101737","author":"X Garc\u00eda-Otero","year":"2021","unstructured":"Garc\u00eda-Otero X, Mondelo-Garc\u00eda C, Gonz\u00e1lez F et al (2021) Anti-inflammatory effect of Tacrolimus\/Hydroxypropyl-\u03b2-cyclodextrin eye drops in an endotoxin-induced uveitis model. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13101737","journal-title":"Pharmaceutics"},{"issue":"4","key":"3844_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","volume":"106","author":"CM Sloper","year":"1999","unstructured":"Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106(4):723\u2013728","journal-title":"Ophthalmology"},{"issue":"7\u20138","key":"3844_CR53","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1080\/09273948.2021.1930063","volume":"30","author":"J Luis","year":"2022","unstructured":"Luis J, Alsaedi A, Phatak S et al (2022) Efficacy of tacrolimus in uveitis, and the usefulness of serum tacrolimus levels in predicting disease control. Results from a single large center. Ocul Immunol Inflamm 30(7\u20138):1654\u20131658","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"3844_CR54","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/IAE.0000000000003836","volume":"43","author":"DA Jabs","year":"2023","unstructured":"Jabs DA, Thorne JE, Wilkins CS et al (2023) Tacrolimus for immunosuppression in patients with noninfectious intermediate, posterior, or panuveitides. Retina (Philadelphia, Pa) 43(9):1480\u20131486","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"5","key":"3844_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","volume":"81","author":"V Garg","year":"2013","unstructured":"Garg V, Jain GK, Nirmal J et al (2013) Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Med Hypotheses 81(5):901\u2013904","journal-title":"Med Hypotheses"},{"issue":"4","key":"3844_CR56","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","volume":"23","author":"X Wu","year":"2023","unstructured":"Wu X, Tao M, Zhu L et al (2023) Pathogenesis and current therapies for non-infectious uveitis. Clinic Exp Med 23(4):1089\u20131106","journal-title":"Clinic Exp Med"},{"issue":"1","key":"3844_CR57","first-page":"61","volume":"1","author":"FN Yal\u00e7inda\u011f","year":"2007","unstructured":"Yal\u00e7inda\u011f FN, Batio\u011flu F, Ari N et al (2007) Aqueous humor and serum penetration of tacrolimus after topical and oral administration in rats: an absorption study. Clinic Ophthalmol (Auckland, NZ) 1(1):61\u201364","journal-title":"Clinic Ophthalmol (Auckland, NZ)"},{"issue":"9","key":"3844_CR58","first-page":"2737","volume":"34","author":"U Pleyer","year":"1993","unstructured":"Pleyer U, Lutz S, Jusko WJ et al (1993) Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 34(9):2737\u20132742","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3844_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1546-0096-9-34","volume":"9","author":"A Taddio","year":"2011","unstructured":"Taddio A, Cimaz R, Caputo R et al (2011) Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case Series Pediatr Rheumatol Online J 9(1):34","journal-title":"Case Series Pediatr Rheumatol Online J"},{"issue":"3","key":"3844_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/ICL.0000000000000162","volume":"42","author":"E Eri\u015f","year":"2016","unstructured":"Eri\u015f E, Y\u00fcksel N, Pirhan D et al (2016) Evaluation of effect of topical tacrolimus treatment on herpetic stromal keratitis in a rat model. Eye Contact Lens 42(3):163\u2013170","journal-title":"Eye Contact Lens"},{"issue":"5","key":"3844_CR61","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.3892\/mmr.2017.7353","volume":"16","author":"Y Yu","year":"2017","unstructured":"Yu Y, Zhong J, Peng L et al (2017) Tacrolimus downregulates inflammation by regulating pro-\/anti-inflammatory responses in LPS-induced keratitis. Mol Med Rep 16(5):5855\u20135862","journal-title":"Mol Med Rep"},{"issue":"6","key":"3844_CR62","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00417-022-05617-6","volume":"260","author":"N Mandal","year":"2022","unstructured":"Mandal N, Yeung SN, Tadrous C et al (2022) Thygeson\u2019s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 260(6):1837\u20131841","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3844_CR63","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.ajoc.2021.101175","volume":"23","author":"J Martin","year":"2021","unstructured":"Martin J, Kopplin L, Costakos D (2021) Syphilitic interstitial keratitis treated with topical tacrolimus. Am J Ophthalmol Case Rep 23:101175","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"3844_CR64","first-page":"240","volume":"9","author":"M Hessen","year":"2014","unstructured":"Hessen M, Akpek EK (2014) Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res 9(2):240\u2013250","journal-title":"J Ophthalmic Vis Res"},{"key":"3844_CR65","doi-asserted-by":"publisher","first-page":"15994","DOI":"10.1038\/s41598-025-87901-9","volume":"15","author":"AA El-Khouly","year":"2025","unstructured":"El-Khouly AA, Ibrahim A, Abdel-Rehim AM et al (2025) Tacrolimus eye drops versus dexamethasone for shield ulcer associated with vernal keratoconjunctivitis: a comparative study. Sci Rep 15:15994. https:\/\/doi.org\/10.1038\/s41598-025-87901-9","journal-title":"Sci Rep"},{"key":"3844_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12886-024-03506-6","volume":"24","author":"J Shimazaki","year":"2024","unstructured":"Shimazaki J, Tomida D, Yagi-Yaguchi Y et al (2024) Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial. BMC Ophthalmol 24:251. https:\/\/doi.org\/10.1186\/s12886-024-03506-6","journal-title":"BMC Ophthalmol"},{"key":"3844_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtos.2024.100913","volume":"35","author":"E Mohammed","year":"2024","unstructured":"Mohammed E, Ribeiro R, Amaral MH (2024) Nano-enabled ocular delivery of anti-inflammatory drugs and calcineurin inhibitors. Ocul Surf 35:1\u201320. https:\/\/doi.org\/10.1016\/j.jtos.2024.100913","journal-title":"Ocul Surf"},{"key":"3844_CR68","doi-asserted-by":"publisher","unstructured":"Ornek K, Karslioglu S (2024) Topical tacrolimus in allergic eye diseases: a systematic review. Beyoglu Eye J; 9(4):ePub. https:\/\/doi.org\/10.14744\/bej.2024.xxxxx.","DOI":"10.14744\/bej.2024.xxxxx"},{"issue":"19","key":"3844_CR69","doi-asserted-by":"publisher","first-page":"10515","DOI":"10.3390\/ijms251910515","volume":"25","author":"MA Grimaudo","year":"2024","unstructured":"Grimaudo MA, Pitorri M, Giannaccare G et al (2024) Hydroxypropyl-\u03b2-cyclodextrin improves ocular delivery of tacrolimus: comparison with ethanol-based drops in preclinical models. Int J Mol Sci 25(19):10515. https:\/\/doi.org\/10.3390\/ijms251910515","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3844_CR70","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/sj.bjp.0707002","volume":"150","author":"CA Harrison","year":"2007","unstructured":"Harrison CA, Bastan R, Peirce MJ et al (2007) Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 150(4):509\u2013518","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3844_CR71","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.bjp.0705522","volume":"140","author":"RD Price","year":"2003","unstructured":"Price RD, Yamaji T, Matsuoka N (2003) FK506 potentiates NGF-induced neurite outgrowth via the Ras\/Raf\/MAP kinase pathway. Br J Pharmacol 140(5):825\u2013829","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3844_CR72","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1152\/physrev.2000.80.4.1483","volume":"80","author":"F Rusnak","year":"2000","unstructured":"Rusnak F, Mertz P (2000) Calcineurin: form and function. Physiol Rev 80(4):1483\u20131521","journal-title":"Physiol Rev"},{"issue":"11","key":"3844_CR73","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1167\/iovs.02-1228","volume":"44","author":"E Sakurai","year":"2003","unstructured":"Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y (2003) Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Investig Ophthalmol Vis Sci 44(11):4845\u20134852","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"3844_CR74","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3109\/02713683.2015.1082187","volume":"41","author":"A Pastor-Clerigues","year":"2016","unstructured":"Pastor-Clerigues A, Serrano A, Milara J et al (2016) Evaluation of the ocular tolerance of three tacrolimus topical pharmaceutical preparations by bovine corneal opacity and permeability test. Curr Eye Res 41(7):890\u2013896","journal-title":"Curr Eye Res"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03844-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:03:44Z","timestamp":1763625824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03844-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3844"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03844-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"1"}}